Antibodies for HIV

This trial tests a new lab-made antibody called ePGT121v1-LS, which targets HIV. Researchers aim to assess its safety, potential side effects, and effectiveness when administered intravenously or subcutaneously, either alone or with two other antibodies, PGDM1400LS and VRC07-523LS. The goal is to determine if these antibodies can safely work together without interference. Individuals in good health, who have tested negative for HIV, and are at low risk of contracting it, might be suitable candidates for this study. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new antibody.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you have taken immune suppressing medicines, certain vaccines, or investigational drugs within specific time frames before the study starts.

Research has shown that the antibodies tested in this study, including ePGT121v1-LS, PGDM1400LS, and VRC07-523LS, have generally been safe and well-tolerated in past trials. When administered together, most participants did not experience serious side effects. For instance, one study found the combination safe for 83% of participants. Another study demonstrated that PGT121, similar to ePGT121v1-LS, was safe and well-tolerated in both individuals with and without HIV.

Researchers are excited about these treatments because they use antibodies like ePGT121v1-LS, PGDM1400LS, and VRC07-523LS, which are engineered to target HIV more precisely than standard antiretroviral therapies. Unlike traditional treatments that require daily pills, these antibodies are administered via infusions or injections, potentially reducing the frequency of doses. This new approach might offer a dual benefit: enhancing convenience for patients and improving the body's ability to fight the virus by directly neutralizing it, which could lead to better long-term control of HIV.

Research has shown that the antibody ePGT121v1-LS holds promise in fighting HIV. In studies, it neutralized 64% of 634 diverse and challenging HIV-1 strains. In this trial, some participants will receive ePGT121v1-LS alone, while others will receive it combined with two other antibodies, PGDM1400LS and VRC07-523LS. This combination targets different parts of the HIV virus, potentially enhancing its overall ability to combat the virus. Previous trials with similar antibody combinations demonstrated positive results in terms of safety and effectiveness against the virus. This suggests it could help control HIV by preventing the virus from infecting healthy cells.¹⁶⁷⁸⁹